Psioxus

Smart Science for Serious Disease

PsiOxus aims to be the world’s leading immuno-oncolytic virus company, delivering medicines of value to patients with cancer.

Our work is product and platform based with a focus on discovering and developing innovative immunotherapies for the treatment of solid tumors. Our products utilize enadenotucirev, our proprietary first generation oncolytic virus and our proprietary platform technology for next generation oncolytic viruses, Tumor-Specific Immuno-Gene Therapy (T-SIGn).

Our world leading scientists and highly experienced management team are based in Oxford, UK and Philadelphia, USA.

AMGEN

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.

Sillajen

SillaJen Inc (Busan and Seoul, S Korea) is the global leader in the development of oncolytic vaccinia immunotherapy with Pexa-Vec (aka JX-594; previously Jennerex Inc) for primary hepatocellular carcinoma (HCC). We reported IV delivery of Pexa-Vec to diverse solid tumors (Nature 2011), and improved overall survival in a randomized dose-finding clinical trial (Nature Med 2013). Initiation of a Phase 3 clinical trial is planned for 2015. Patients with advanced first-line HCC will be randomized to treatment with Pexa-Vec followed by sorafenib versus sorafenib alone, with a primary endpoint of overall survival duration.

Oxford Genetics

Oxford Genetics is a synthetic biology company taking an engineering approach to DNA, virus and cell line design, optimization and development. The business has a number of technologies enabling the delivery of complex solutions for the life sciences, including proprietary plasmids for protein manufacture, and improved lentivirus production systems for gene therapy applications. These systems include proprietary promoters to maximize yield and have been developed using proprietary bioinformatics software for gene optimization. Our proprietary bioinformatics and DNA design algorithms are designed to improve recombinant protein expression. Oxford Genetics Ltd has a track record of delivering DNA design and cell line development projects for the improved production of antibodies, vaccines and viruses.

sartorius

Now part of Sartorius Stedim Biotech, we provide integrated upstream development services for your Biopharmaceutical drug development programs.

Sartorius is a global leader in cell line development, cell bank manufacturing, biosafety and analytical testing services, supporting customers through their drug’s development life cycle; from DNA to GMP lot release testing on DS/DPs. Alongside our portfolio of off-the-shelf assays to enable faster Speed to Clinic, we also perform custom assay development.

In addition to being leaders in contract testing and research services, we also pride ourselves in our commitment to delivering service excellence. With a robust internal R&D program, we are constantly adding innovative analytical technologies to our portfolio of services in order to align with changing market demands. With our innovative approach and dedicated client managers, we ensure projects are managed efficiently, cost-effectively, and completed on-time.

Benefit from our integrated services to efficiently advance your biologic drug candidates rapidly from early stage development through to commercialization.

Replimune

Oncolytic immunotherapy is an emerging class of cancer therapeutics which exploit the ability of viruses to selectively replicate in and kill tumor tissue, while at the same time inducing a potent, patient-specific, anti-tumor immune response. Oncolytic viruses have the unique ability to generate a systemic immune response to the patient’s particular complement of tumor antigens, including neoantigens, with a truly off-the-shelf and practical approach. This potentially solves a current ‘holy grail’ of immune-oncology research, i.e. the development of truly practical patient-specific tumor neoantigen vaccines. Oncolytic viruses also potently activate innate immunity, including through TLRs and STING, meaning that altogether oncolytic immunotherapies bundle multiple immune oncology approaches into one. This particularly the case if, as for Replimune’s products, these are then used to also deliver multiple therapeutic proteins to tumors too.

Vyriad

Vyriad is a clinical stage, biopharmaceutical company based in Rochester, MN.  Founded by a passionate team of researchers and clinicians with extensive experience in development and translation of novel oncolytic therapies for the treatment of cancer.

Vyriad strives to develop potent, safe and cost-effective cancer therapies in areas of unmet need. We are developing powerful Oncolytic virus therapies, utilizing engineered viruses designed to selectively and rapidly destroy cancer.  We have exclusively licensed the powerful Vesicular Stomatitis Virus (VSV) and measles Virus (MV) Oncolytic platforms.

ASGCT

ASGCT is the primary membership organization for scientists, physicians, patient advocates, and professionals involved in gene and cell therapy. The Society’s mission is to advance knowledge, awareness, and education leading to discovery and clinical application of gene and cell therapies to alleviate disease. ASGCT also publishes the Molecular Therapy family of journals, including Molecular Therapy – Oncolytics, an online open-access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer.

Turnstone

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. The company’s first-of-its-kind investigational oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, with the goal of preventing recurrence and delivering a cure. Turnstone Biologics’ robust pipeline of early-stage investigational therapies, based on its Maraba (MG1) oncolytic virus platform, are in development for solid tumors. In addition to the MAGEA3 therapy currently in the clinic, Turnstone Biologics expects to enter the clinic in early 2018 with a therapy for HPV+ cancers, and is also developing medicines for multiple other cancers. These immunotherapies are being evaluated as monotherapies and in combination with other cancer therapies, including checkpoint inhibitors. Turnstone has been financed by Versant Ventures, OrbiMed, F-Prime Capital Partners and FACIT. Turnstone recently entered a research, option and license agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company, whereby AbbVie obtained an exclusive option to license up to three of Turnstone’s next-generation oncolytic viral immunotherapies

StemImmune

StemImmune is a clinical-stage biotechnology company, focused on developing paradigm-changing live vector-mediated immunotherapies for the treatment of a variety of devastating cancers for which there are no effective treatments.  Amongst the technologies the company is developing, StemImmune has pioneered a transformational cell-mediated oncolytic viral immunotherapy platform designed to unleash a targeted and deadly attack on cancer, while sparing a patient’s healthy tissues and cells.  This proprietary technology leverages a stealth, autologous cell-based system to deliver potent oncolytic viral payloads directly to the tumor. The platform is designed specifically to target and kill cancer cells, while engaging the patient’s immune system to recognize and fight against cancer.   Headquartered in San Diego, StemImmune was founded in 2014 by Professor Aladar Szalay, world-renowned leader in the use of armed, live-vector systems to target and eliminate cancer.

Novasep

Novasep is a CDMO specialized in viruses & viral vectors production for tox, clinical and commercial phases. Novasep offers global and integrated services from process development to fill and finish. For more than 15 years, Novasep has acquired experience in manufacturing viral vectors (lentivirus, AAV, ADV…) for gene therapy and vaccination. Our unique manufacturing capabilities and our strong track record can address all manufacturing needs thanks to a mastery of both cultivation and purification technologies as well as virus-dedicated process development methodology. Our ongoing investment in new commercial assets, addressing both drug substance and drug product manufacturing processes, will help to contribute to your project’s success. Come and meet us at booth number 6

Tocagen

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in- class, broadly
applicable product candidates designed to activate a patient's immune system against their own cancer.
Tocagen's lead investigational product candidate, Toca 511 & Toca FC, is under evaluation in a pivotal
Phase 3 trial for recurrent high-grade glioma (HGG), a disease with significant unmet medical need. The
U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy
Designation for the treatment of recurrent HGG and the European Medicines Agency (EMA) has granted
Toca 511 PRIME (PRIority MEdicines) designation for the treatment of HGG. The company is based in
San Diego California.

Astra Zeneca

AstraZeneca Plc. is a global pharmaceutical company with a major UK presence and is a FTSE 100 company. Our mission is to push the boundaries of science to deliver life-changing medicines and healthcare systems. We are committed to making a meaningful difference to patient health and we believe the best way we can do this is to be led by the translation of science. We are continuously working to make the most of the opportunities that frontier science and technologies bring to the search for new medicine and we share this passion with the scientific, healthcare and business community of the UK. 

Ignite

IGNITE Immunotherapy is working to unlock the full potential of cancer immunotherapy. Our optimized intravenous oncolytic cancer vaccines are designed to complement approved immune checkpoint inhibitors by igniting an immune response to patients’ cancers. Our purpose is to cure cancer patients through combination immunotherapy with our intravenous oncolytic vaccines.

The brain tumour charity

The Brain Tumour Charity is at the forefront of the fight to defeat brain tumours, making a difference every day to the lives of people with a brain tumour and their families.  We fund pioneering research to increase survival, raise awareness of the symptoms and effects of brain tumours and provide support for everyone affected to improve quality of life.

CRUK Oxford Center

The CRUK Oxford Centre is a network and partnership between Oxford University, Oxford University Hospitals NHS Foundation Trust and Cancer Research UK. It comprises over 600 members from 25 different Departments, Units and Institutes of the University and the NHS Trust. It harnesses Oxford’s world-leading cancer research to ensure rapid translation from scientific discovery to treatments for patients.

The Oxford Centre is an inclusive network, which supports and connects people working across a range of disciplines and aims to facilitate research collaboration on a local, 

VCN

VCN Biosciences is a privately-owned company focused in the development of new therapeutic approaches for tumors that lack effective treatment. The company uses oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumor cells. The selectivity of VCN oncolytic adenoviruses allows their systemic administration, which is especially relevant for the treatment of disseminated cancer. Contrary to chemotherapy, the ability of oncolytic virus to self-amplify in tumor cells results in an effective dose increase with time. These properties highlight VCN candidates as promising alternatives for the treatment of refractory tumors such as pancreatic adenocarcinomas, which is the current tumor target for its most advanced candidate, VCN-01.

Merck

MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A.

Invent With Us

MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs.  Our scientific advances have made a difference in the lives of millions of patients worldwide… and many of these advances were the result of partnerships.  In 2016, more than 60% of our human health sales were attributable to alliance partnerships and patents and we continue to work with our partners in some of the most challenging areas of biomedical research. 

With more than 100 business development transactions since 2015, our team has experience working on collaborations from discovery to clinical-stage programs regardless of therapeutic area or modality.  We believe that by working together we can play a major role in transforming global health care.  Together we can invent for life. 

Viralytics

Viralytics Limited is focused on the development and commercialisation of oncolytic
immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer
cells. Our lead product candidate is CAVATAK®, a genetically unmodified proprietary formulation of
the common cold Coxsackievirus Type A21, is now being evaluated in multiple clinical trials in
various combinations and modes of administration against a range of cancer indications. CAVATAK
binds to specific receptor proteins highly expressed on a range of tumour cell types, and acts to
destroy local as well as metastatic cancer cells through cell lysis and the potential generation of a
specific immune response against the cancer cells.
CAVATAK-induced changes in the tumour microenvironment suggest a strong local and systemic
anti-tumour response, particularly when used in combination with checkpoint inhibitors. These
changes include an increase in immune cell infiltration and the up-regulation of immune-checkpoint
molecules such as PD-L1.

Imanis Life Sciences

Imanis Life Sciences was founded by a group of Mayo Clinic scientists with deep expertise in translatable oncolytic virotherapy research and a mission to improve the field of noninvasive imaging. We have become a trusted adviser and innovator to our global customer base in academia and industry. Our encompassing product line features oncolytic viruses, as well as our ground-breaking NIS technology, reporter gene cell lines, and lentiviral vectors. Imanis provides tailored services for customers developing oncolytic virotherapy, cell and gene therapies, and regenerative medicine products. Our heritage in translational research allows us to be knowledgeable about the potential setbacks our customers face.  We are dedicated to providing quality products, services, and support to help them overcome these challenges.